COVID-19 Therapeutics Fact Sheet

The spectrum of medical therapies to treat COVID-19 is rapidly evolving and these medications are used at different times. Therapeutics are indicated for the treatment of mild to moderate COVID-19 in non-hospitalized patients with laboratory-confirmed SARS-CoV-2 infection, who are at high risk for progressing to severe disease and/or hospitalization.

People who test positive for the virus are more likely to get very sick from COVID-19, especially:

- Older adults (age 50 years or more, with risk increasing with age)
- People who are unvaccinated
- <u>Individuals with certain medical conditions</u>, such as chronic lung disease, heart disease or a weakened immune system

Treatment Options

It is important to check with the Administration for Strategic Preparedness and Response (ASPR) <u>Treatment Options</u> <u>for COVID-19</u> prior to initiating therapy, as recommendations are frequently updated due to viral mutations.

Therapeutic	Type of treatment	Start time after symptoms first appear
Paxlovid	Oral antiviral (pills)	As soon as possible and up to 5 days
Lagevrio (molnupiravir)	Oral antiviral (pills)	As soon as possible and up to 5 days
Veklury® (remdesivir)	IV infusion antiviral	As soon as possible and up to 7 days

^{*} Current as of January 30, 2023

Every patient who tests positive for COVID-19 should be evaluated to determine whether the use of an available therapeutic is appropriate. Therapeutics can prevent serious illness and save the lives of high-risk individuals who would otherwise be at risk of severe complications.

Resources:

- <u>ASPR COVID-19 Therapeutics Announcements</u> | DHHS Administration for Strategic Preparedness and Response (ASPR)
- COVID-19 Treatments and Medications | Centers for Disease Control and Prevention (CDC)
- <u>COVID-19 Therapeutics Locator</u> | DHHS ASPR
- Paxlovid Eligibility Screening Checklist Tool for Prescribers | Food and Drug Administration (FDA)
- National Institutes of Health's COVID-19 Treatment Guidelines

Fact sheets for health care providers:

- Lagevrio/Molnupiravir | FDA
- Paxlovid | FDA
- Veklury/Remdesivir Prescribing Information Gilead Sciences, Inc.



